FDA nod to Boehringer Ingelheim’s JASCAYD for progressive pulmonary fibrosis in adults
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Subscribe To Our Newsletter & Stay Updated